Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study

Affiliations

• ¹ General Hospital Evangelismos, Athens, Greece.
• ² Hospital Universitario de Salamanca, Salamanca, Spain.
• ³ The Hugh and Josseline Langmuir Centre for Myeloma Research, Imperial College London, London, UK.
• ⁴ Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
• ⁵ School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
• ⁶ St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria, Australia.
• ⁷ Department of Hematology, Cherkassy Regional Oncological Center, Cherkassy, Ukraine.
• ⁸ Department of Hemato-oncology, University Hospital Ostrava, University of Ostrava, Ostrava, Czech Republic.
• ⁹ Department of Hematology, CHU la Miletrie and Inserm CIC 1402, Poitiers, France.
• ¹⁰ Nil Ratan Sircar Medical College and Hospital, Kolkata, India.
• ¹¹ State Cancer Institute, Indira Gandhi Institute of Medical Sciences, Patna, India.
• ¹² Cross Cancer Institute, Edmonton, Alberta, Canada.
• ¹³ Kings College Hospital NHS Foundation Trust, London, UK.
• ¹⁴ University Hospitals of Leicester NHS Trust, Leicester, UK.
• ¹⁵ City Clinical Hospital #40, Moscow, Russian Federation.
• ¹⁶ Baylor University Medical Center, Dallas, Texas, USA.
• ¹⁷ University of Nantes, Nantes, France.
• ¹⁸ Karyopharm Therapeutics, Newton, Massachusetts, USA.
• ¹⁹ Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
• ²⁰ Medical University of Silesia, Katowice, Poland.